CBAI.OB

[crazy23]

When looking at cord blood chart at the end of a the day is it possible that an inverted head and shoulders is forming.  Im pretty new to the technical stuff, so I figured you guys could confirm.  Thanks.  Sorry I couldn't figure out how to post the chart.

[golfqtee]

Well, I'm stuck in here.  Hope all your good tidings pan out!  In a year or so it may come back to .52 where I bought.   Happy trading!

[atalltexan]

Nice point to reenter.  Starting to climb again on nice volume.

[catrader]

per an e-mail i got, it says might run to 0.40 based on MACD, on-balance-volume, relative
strength, and accumulation-distribution .  so bought small position. we shall see if it pans out.  a company in a promising area I would say.

[sebfr]

Hi,
buy this stock at 0.205
target at 0.750 (> 300% !!!)
stop loss at 0.170

news :
Bio-Matrix Scientific Sees Completion of New Stem Cell Cryogenic Labs in December
11/9/05       

SAN DIEGO, Nov 09, 2005 (BUSINESS WIRE) --
Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) announced today that it anticipates its Stem Cell Cryogenic Labs will be completed by December this year. The Company believes it will see revenue from stem cell banking within the first quarter of 2006.

Bio-Matrix' new 15,000 sq. ft. facility, located in the heart of the San Diego biotechnology corridor, is currently in the process of being upgraded in order to house the Company's state-of-the-art secure Cryogenic Stem Cell Bank, 3 Research labs, aseptic cellular/tissue processing rooms, hematology, microbiology and flow cytometry laboratories.

Dr. Geoffrey O'Neill, President of Bio-Matrix, stated, "We intend for The Bio-Matrix' laboratories to be a state-of-the-art, good manufacturing practices (cGMP) and good tissue practices (cGTP) compliant facility. The Company has contracted with Carda Construction, which is a San Diego-based Construction Company and experts in Laboratory and Clean Room construction."

Bio-Matrix' Managing Director, Brian Pockett, stated, "This represents a major milestone towards full cryogenic operations. We believe that the construction of Cryogenic labs and new clean rooms will assure the superior competitiveness of Bio-Matrix and the company's greater responsiveness to the growing demand for Stem Cell Cryogenics in an increasingly strong market."

About Bio-Matrix Scientific Group Inc.

Bio-Matrix Scientific Group Inc. is a development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Other companies in the same industry as Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) are Cord Blood America (OTCBB:CBAI), StemCells Inc. (Nasdaq:STEM) and Regeneration Technologies (OTCBB:RTIX).

Technicals :
Good support at 0.190
Good retracement at 0.872...SOON the third wave (eliott wave)
MACD > 0 and well oriented
divergence in RSI and MACD

[gmarc66]

Hey Seb_spa...how do u think it will do today with this news out, sounds pretty good

2005-11-22 08:00:33 
Cord Blood America Reports Revenues Up 96 Percent for First Nine Months of Fiscal Year 


LOS ANGELES, Nov. 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc.
(OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation
company which is focused on bringing the life saving potential of stem cells
to families nationwide, today announced that revenues for the nine months
ended September 30, 2005, increased 96 percent to approximately $1.9 million
compared to revenues of approximately $968,000 for the same period in 2004.
The Company said increased marketing efforts, consistent follow-up with
potential customers by telephone, direct mail and e-mail, plus the addition of
sales people were some of the key reasons for the increase in revenue.
Revenues for the three months ended September 30, 2005 increased 27% to
approximately $431,000 compared to approximately $339,000 for the same three
months in 2004.
Chairman and CEO Matthew L. Schissler said Cord Blood America continues to
be pleased with its operating performance. "It is especially interesting to
note an increase in repeat business and referrals by existing customers," Mr.
Schissler said.
Cord Blood America also announced that gross profit increased 77 percent
for the first nine months of 2005 to approximately $464,000 compared to
approximately $262,000 for the same period last year. "We are excited by our
growth and our ability to explain the importance of storing umbilical cord
blood, both directly to parents and physicians and also through our
outstanding web site, www.cordpartners.com. Additionally, we believe our
$269 Annual Payment Option makes this life-saving effort affordable to more
families," emphasized the CEO.
Mr. Schissler said the Company will continue focus on its direct to
consumer sales strategy, but will also put significant emphasis on educating
physicians, hospitals and other caregivers. Cord Blood America is developing
new sales opportunities with more strategic partnerships with Obstetrics and
Gynecology practices and other medical professionals working closely with
expectant families. "We believe execution of these partnerships will enhance
our long-term growth and profitability," Cord Blood America's CEO said.
The information provided in this press release provides only a portion of
the Company's overall financial position. For complete details please view
the latest 10-QSB filing at
http://www.sec.gov/Archives/edgar/data/1289496/000111650205002649/0001116502-
05-002649-index.htm
This press release is available on the Cord Blood America IR HUB for
investor commentary, feedback and questions. Investors are asked to visit
http://www.agoracom.com/IR/CordBloodAmerica . Alternatively, investors are
asked to e-mail all questions and correspondence to [email protected] where
they can also request addition to the investor e-mail list to receive all
future press releases and correspondence directly.
About Cord Blood America
Cord Blood America, Inc. (OTC Bulletin Board: CBAI) is the parent company
of Cord Partners, which facilitates umbilical cord blood stem cell
preservation for expectant parents and their children. Its mission is to be
the most respected stem cell preservation company in the industry. Collected
through a safe and non-invasive process, cord blood stem cells offer a
powerful and potentially life-saving resource for treating a growing number of
diseases, including certain cancers, leukemia, blood, and immune disorders.
For more information on how this precious lifeline can benefit your family,
visit http://www.cordpartners.com. For investor information, visit
www.cordblood-america.com.

[sebfr]

Great...BUYYYYYYYYYYYYYYY

[sebfr]

Hi,

CBAI = Penny stock of the day..

First target at 0.50...
Very few risk...

Technically, we have an ascending triangle breakout on price and RSI...

[GatewayStocks]

when is this toxic cornell financing going to be over?

[sebfr]

Hi,

CBAI is still the penny stock of the day !

news :
Cord Blood America Says President Bush Signing Umbilical Cord Blood Bill is a Key to the Future of Industry; Will Save Lives
12/21/2005 5:00:30 AM
LOS ANGELES, Dec 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Cord Blood America, Inc. (CBAI), the umbilical cord blood stem cell preservation company which is focused on bringing the life saving potential of stem cells to families nationwide, said that the signing by President Bush of The Stem Cell Therapeutic and Research Act of 2005, following recent overwhelmingly approval by Congress, brings the "best kept medical secret" to the forefront in fighting terrible conditions and diseases.
"Umbilical cords are a non-controversial, richly endowed source of stem cells. Currently most hospitals simply throw them away. Thousands of Americans suffer or die needlessly each year because of the unavailability of matching stem cells. Cord Blood America is in the forefront in offering the affordable service to families for the storage of the umbilical cord blood at the time of birth," said Matthew Schissler, Cord Blood America CEO.

Rep. Chris Smith (R -- N.J.), co-sponsor of the legislation, said: "Cord blood stem cells are already treating patients. The New York Blood Center alone has treated thousands of patients with more than 65 diseases, including sickle-cell disease, leukemia and osteoporosis. Cord blood has also been used to treat neurological conditions, debunking the idea that cord blood cells can only treat blood disorders."

"On the contrary," the New Jersey Congressman said, "14 separate studies have shown that adult and cord blood stem cells possess the capability to transform into most tissue types in the body, including nerve cells, heart cells and insulin-secreting cells. This ability to transform offers the potential to yield a cure for spinal cord injuries and diseases including Parkinson's, diabetes and Alzheimer's."

"This recognition by Congress and the President of the importance of saving umbilical cord blood is both heartening and crucial to future successes in saving lives," Mr. Schissler said.

This press release is available on the Cord Blood America IR HUB for investor commentary, feedback and questions. Investors are asked to visit http://www.agoracom.com/IR/CordBloodAmerica . Alternatively, investors are asked to e-mail all questions and correspondence to [email protected] where they can also request addition to the investor e-mail list to receive all future press releases and correspondence directly.

About Cord Blood America

Cord Blood America (CBAI) is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. For more information on how this precious lifeline can benefit your family, visit http://www.cordpartners.com. For investor information, visit www.cordblood-america.com.

Technicals :
Volume : Very high volume
Indicators : RSI > 50 and MACD > 0 and +di > -di and ADX < 23 and adx rising
Eliott wave : beginning the third wave
Chart pattern : Ascending triangle breakout
Fibonacci ratio : 0.885...Good retracement
Support and resistance : Price close to his support at about 0.18-0.21
Candelstick : Bullish Engulfing (Bullish Reversal Patterns)

[Stocky2000]

CBAY - moves up with this news (i catched the train early at 0.143)

Cord Blood America Continues Efforts to Prevent the Naked Short Selling of Its Stock With BUYINS.NET
Tuesday March 14, 5:00 am ET


LOS ANGELES, March 14 /PRNewswire-FirstCall/ -- BUYINS.NET, www.buyins.net, is re-iterating coverage of Cord Blood America, Inc (OTC Bulletin Board: CBAI - News) after releasing the latest short sale data to March 2006. From January 2005 to March 2006 approximately 76.9 million total aggregate shares of CBAI have traded for a total dollar value of nearly $30.4 million. The total aggregate number of shares shorted in this time period is approximately 5.9 million shares. The CBAI SqueezeTrigger price of $0.40 is the volume weighted average short price of all short selling in CBAI. The next short squeeze is expected to begin when shares of CBAI close above $0.15, where 332,172 shares have been shorted. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://buyins.net .



    Month       Total Volume    Short Volume   Avg. Price   Short Dollar Value

    January '05       40,600        3,126        $1.12            $3,501
    February         248,694       19,149        $0.67           $12,734
    March          1,059,520       81,583        $0.29           $23,863
    April          1,623,832      125,035        $0.20           $25,320
    May            2,997,871      230,836        $0.15           $33,471
    June          11,991,757      923,365        $0.40          $364,729
    July          27,871,660    2,146,118        $0.57        $1,223,287
    August         8,595,442      661,849        $0.41          $268,049
    September      4,746,068      365,447        $0.30          $110,548
    October        2,945,938      226,837        $0.24           $53,647
    November       2,469,900      190,182        $0.23           $43,989
    December       4,847,015      373,220        $0.21           $79,757
    January '06    3,122,228      240,412        $0.19           $45,318
    February       3,061,410      235,729        $0.16           $37,717
    March          1,316,048      101,336        $0.15           $15,200

    Total:        76,937,983    5,924,225        $0.40        $2,341,131

    *short volume is approximated using a proprietary algorithm.
    **average short price is calculated using a volume weighted average short
     price.
    ***short volume is the total short trade volume and does not account for
     covers.



                   CBAI On OTCBB Naked Short Threshold List

    On List                   Off List            # Days

    May 27, 2005             May 31, 2005            2
    June 20, 2005           June 20, 2005            1
    July 29, 2005         August 22, 2005           17
    February 14, 2006   February 21, 2006            5



Cord Blood America, Inc has been on the OTCBB Naked Short Threshold list 4 times. Brokerage firms have been out of compliance with Regulation SHO once. Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. SEC Regulation SHO, under the Securities Exchange Act of 1934, mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.

About Cord Blood America Inc.

Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News) is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Stem cells have proven successful in replacing other cells that are damaged or missing due to a disease. Unlike embryonic stem cells, there is no controversy with the collection or use of these stem cells. Cord Blood America facilitates the harvest of stem cells from umbilical cords that traditionally have been discarded at birth for the sole use of the family. For more information on how this precious lifeline can benefit your family, visit http://www.cordpartners.com . For investor information, visit www.cordblood-america.com .

About BUYINS.NET

[waxweazle]

CBAY - moves up with this news (i catched the train early at 0.143)

Cord Blood America Continues Efforts to Prevent the Naked Short Selling of Its Stock With BUYINS.NET
Tuesday March 14, 5:00 am ET


LOS ANGELES, March 14 /PRNewswire-FirstCall/ -- BUYINS.NET, www.buyins.net, is re-iterating coverage of Cord Blood America, Inc (OTC Bulletin Board: CBAI - News) after releasing the latest short sale data to March 2006. From January 2005 to March 2006 approximately 76.9 million total aggregate shares of CBAI have traded for a total dollar value of nearly $30.4 million. The total aggregate number of shares shorted in this time period is approximately 5.9 million shares. The CBAI SqueezeTrigger price of $0.40 is the volume weighted average short price of all short selling in CBAI. The next short squeeze is expected to begin when shares of CBAI close above $0.15, where 332,172 shares have been shorted. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://buyins.net .



    Month       Total Volume    Short Volume   Avg. Price   Short Dollar Value

    January '05       40,600        3,126        $1.12            $3,501
    February         248,694       19,149        $0.67           $12,734
    March          1,059,520       81,583        $0.29           $23,863
    April          1,623,832      125,035        $0.20           $25,320
    May            2,997,871      230,836        $0.15           $33,471
    June          11,991,757      923,365        $0.40          $364,729
    July          27,871,660    2,146,118        $0.57        $1,223,287
    August         8,595,442      661,849        $0.41          $268,049
    September      4,746,068      365,447        $0.30          $110,548
    October        2,945,938      226,837        $0.24           $53,647
    November       2,469,900      190,182        $0.23           $43,989
    December       4,847,015      373,220        $0.21           $79,757
    January '06    3,122,228      240,412        $0.19           $45,318
    February       3,061,410      235,729        $0.16           $37,717
    March          1,316,048      101,336        $0.15           $15,200

    Total:        76,937,983    5,924,225        $0.40        $2,341,131

    *short volume is approximated using a proprietary algorithm.
    **average short price is calculated using a volume weighted average short
     price.
    ***short volume is the total short trade volume and does not account for
     covers.



                   CBAI On OTCBB Naked Short Threshold List

    On List                   Off List            # Days

    May 27, 2005             May 31, 2005            2
    June 20, 2005           June 20, 2005            1
    July 29, 2005         August 22, 2005           17
    February 14, 2006   February 21, 2006            5



Cord Blood America, Inc has been on the OTCBB Naked Short Threshold list 4 times. Brokerage firms have been out of compliance with Regulation SHO once. Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. SEC Regulation SHO, under the Securities Exchange Act of 1934, mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.

About Cord Blood America Inc.

Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News) is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Stem cells have proven successful in replacing other cells that are damaged or missing due to a disease. Unlike embryonic stem cells, there is no controversy with the collection or use of these stem cells. Cord Blood America facilitates the harvest of stem cells from umbilical cords that traditionally have been discarded at birth for the sole use of the family. For more information on how this precious lifeline can benefit your family, visit http://www.cordpartners.com . For investor information, visit www.cordblood-america.com .

About BUYINS.NET

NICE CALL

This will run look to

FBVG

[Stocky2000]

breakout on a weekly basis...keep it on the radar...maybe they start a news campaign wouln t wonder me...this firm had revenue increas of 96% last quarter...i dont know when the next earnings will be.

[setravis]

Been some time since any talking going on about this one.......
Updated chart look...Volume: 61,468,910

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
24.64%above 13-day MA
129.25%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $4.67 
P/E Ratio: N/A 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[setravis]

Press Release Source: Cord Blood America, Inc.


In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
Thursday February 5, 8:00 am ET


SANTA MONICA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, explained that the Company is very close to becoming cash flow positive.


The complete interview is available at http://www.stoxrox.com/cbai-feb-b.mp3 . "2009 is a tipping point year for Cord Blood America. We will continue our organic growth strategy, adding new health insurance partners and possible new acquisitions, while continuing to reduce debt," Mr. Schissler said.

Cord Blood America's CEO said he was encouraged that more Federal spending on stem cell research under President Obama could lead to more stem cell therapies which, in turn, will lead to more families storing stem cells. "The stem cell agenda is front and center with the new Administration," Mr. Schissler said.

Cord Blood America's CEO also referenced the cover story of the new Time magazine, which cited breakthroughs using stem cells to treat Parkinson's, heart disease and diabetes. "Investors should understand, in storing umbilical cord blood stem cells, we have a significant biological annuity with low bad debt ratio, strong gross profits, and a low cost structure in place that will allow us to take full advantage of the expected increase in the storage of stem cells," the Company's founder said.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.


    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    [email protected]




--------------------------------------------------------------------------------
Source: Cord Blood America, Inc.